GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

The results further undermine Relvar Ellipta, which is already struggling to establish itself in the COPD market. The drug is positioned as a follow-up product to GSK’s blockbuster Advair ...

Teva Pharmaceutical Industries Ltd. ADR-1.87% $19.76B ...

incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 38,541.57 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...

Innoviva Specialty Therapeutics, Inc., ("IST") a subsidiary of Innoviva, Inc. , today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, ...